Binds Enzyme Patents (Class 424/146.1)
-
Publication number: 20130064824Abstract: The present application provides a pharmaceutical composition for administration to a patient suffering from diabetes and other metabolic disorders, the composition comprises a) an activated-potentiated form of an antibody to human insulin receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.Type: ApplicationFiled: July 15, 2011Publication date: March 14, 2013Inventor: Oleg Iliich Epshtein
-
Publication number: 20130058982Abstract: The present invention relates to a method of treating Alzheimer's disease by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase.Type: ApplicationFiled: July 15, 2011Publication date: March 7, 2013Inventor: Oleg Iliich Epshtein
-
Patent number: 8383781Abstract: An antibody or antibody preparation being capable of specifically binding the amino acid sequence of NF-&kgr; B-inducing kinase (NIK) MAP3K14, or a specific portion thereof, and of thereby regulating a biochemical activity of NIK, and/or enabling detection of NIK or a specific portion thereof.Type: GrantFiled: October 5, 2004Date of Patent: February 26, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: David Wallach, Parameswaran Ramakrishnan
-
Patent number: 8383123Abstract: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.Type: GrantFiled: January 20, 2012Date of Patent: February 26, 2013Assignee: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Rajesh Vij
-
Patent number: 8383111Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQWTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.Type: GrantFiled: March 30, 2010Date of Patent: February 26, 2013Inventor: Kai Y. Xu
-
Patent number: 8377437Abstract: The present invention concerns antibodies to c3b and the prevention and treatment of complement-associated disorder using such antibodies.Type: GrantFiled: July 18, 2011Date of Patent: February 19, 2013Assignee: Genentech, Inc.Inventor: Menno Van Lookeren Campagne
-
Publication number: 20130022611Abstract: The invention provides methods and compositions for modulating hepsin activity and the uPA/plasmin pathway, in particular by regulating pro-uPA activation by hepsin.Type: ApplicationFiled: May 25, 2012Publication date: January 24, 2013Applicant: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Paul M. Moran
-
Publication number: 20130017207Abstract: Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Applicant: Gilead Biologics, Inc.Inventors: Victoria SMITH, Alison Kay Holzer
-
Publication number: 20130004504Abstract: A method of affecting a multimeric protein comprising an equilibrium of assembly states, each assembly having a plurality of units, wherein each of the units comprises a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms under four conditions, wherein the method comprising: applying to the multimeric protein a composition comprising a compound adapted to affect formation of an active form of the multimeric protein; associating the composition with an active form of the multimeric protein; and promoting the multimeric protein to assemble into the active form, thereby affecting the multimeric protein to form the active form, wherein the multimeric protein is phenylalanine hydroxylase.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Applicant: Fox Chase Cancer CenterInventor: Eileen K. JAFFE
-
Patent number: 8343494Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: GrantFiled: July 15, 2009Date of Patent: January 1, 2013Assignee: Aventis Pharmaceuticals Inc.Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
-
Patent number: 8344114Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: September 23, 2011Date of Patent: January 1, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A Hammond
-
Publication number: 20120321672Abstract: The present invention relates to a method of treating attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) by administration of activated-potentiate form of antibodies to brain-specific protein S-100 and activated-potentiate form of antibodies to endothelial NO synthase.Type: ApplicationFiled: July 15, 2011Publication date: December 20, 2012Inventor: Oleg Iliich Epshtein
-
Publication number: 20120294800Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: November 18, 2010Publication date: November 22, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Publication number: 20120282267Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.Type: ApplicationFiled: May 2, 2012Publication date: November 8, 2012Applicant: ViroBay, Inc.Inventor: Robert Booth
-
Publication number: 20120276106Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: ApplicationFiled: June 28, 2012Publication date: November 1, 2012Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Patent number: 8293240Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: GrantFiled: February 23, 2009Date of Patent: October 23, 2012Assignee: The Regents of the University of ColoradoInventors: Martha Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Publication number: 20120263647Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: December 16, 2011Publication date: October 18, 2012Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Patent number: 8287860Abstract: The invention relates to the isolation, characterization and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti, L reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using recombinant means and to the use of same as an immunogen for the production in vertebrates of antibodies that neutralise the corresponding venom and the respective fragments F(ab?)2. The invention further relates to the use of recombinant sphingomyelinases D as part of an antigen matrix which can be used in the immunopurification of antibodies and the fragments thereof or as part of any diagnostic device used to obtain clinical confirmation that the causal agent of poisoning in a patient is a spider of the Loxosceles genus.Type: GrantFiled: August 29, 2005Date of Patent: October 16, 2012Assignee: Universidad Nacional Autonoma de Mexico and Laboratorios Silanes S.A. de C.V.Inventors: Alejandro Olvera Rodriguez, Roberto Pablo Stock Silberman, Blanca Margarita Ramos Cerrillo, Rosana Sanchez-Lopez, Alejandro Alagon Cano
-
Publication number: 20120258115Abstract: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.Type: ApplicationFiled: April 11, 2012Publication date: October 11, 2012Inventor: Elizabeth SHANAHAN-PRENDERGAST
-
Publication number: 20120258146Abstract: The present invention relates to a method of treating organic disease of the nervous system, psychoorganic syndrome or encephalopathy of various genesis by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase.Type: ApplicationFiled: July 15, 2011Publication date: October 11, 2012Inventor: Oleg Iliich Epshtein
-
Publication number: 20120251584Abstract: The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.Type: ApplicationFiled: July 15, 2011Publication date: October 4, 2012Inventors: Oleg Iliich Epshtein, Svetlana Alexandrovna Sergeeva, Liudmila Fyodorovna Dolgovyh, Vladmir Ivanovich Petrov
-
Publication number: 20120240245Abstract: The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are nonhuman transgenic animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD. Several preferred embodiments of the therapeutic compositions and animal models are based on target genes MT1-MMP and casein kinase 1 epsilon (CK1?), phagocytosis-related genes found to be over-expressed in human donor eye samples from patients having both wet and dry forms of AMD.Type: ApplicationFiled: October 25, 2011Publication date: September 20, 2012Inventors: GEORGE INANA, MARGARET JEAN MCLAREN
-
Publication number: 20120219557Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: MEDAREX, INC.Inventors: Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
-
METHODS FOR TREATING CONDITIONS MEDIATED BY THE INFLAMMATORY CYTOKINE CASCADE USING GAPDH INHIBITORS
Publication number: 20120219546Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.Type: ApplicationFiled: August 17, 2010Publication date: August 30, 2012Applicant: The Feinstein Institute for Medical ResearchInventors: Kevin Tracey, William Parrish -
Publication number: 20120219558Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9) are disclosed. Said antagonists are effective in the inhibition of PCSK9 function and thereby provide compositions of matter useful for the treatment of conditions associated with PCSK9 activity. The present invention further discloses nucleic acids encoding PCSK9 antagonists as well as methods of making and using PCSK9 antagonists.Type: ApplicationFiled: September 15, 2010Publication date: August 30, 2012Inventors: Yan Ni, Ayesha Sitlani, Shilpa Pandit, Dale Lewis, Xun Shen, Sharon Lobo, Timothy McCabe, Jon Condra, Rose Cubbon, Fubao Wang
-
Publication number: 20120213794Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: October 29, 2010Publication date: August 23, 2012Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
-
Patent number: 8236316Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: November 21, 2008Date of Patent: August 7, 2012Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20120195886Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of agonizing NKA activity through administration of the peptides or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventor: Kai XU
-
Patent number: 8222375Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: GrantFiled: December 8, 2006Date of Patent: July 17, 2012Assignee: MEDAREX, Inc.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
-
Publication number: 20120177656Abstract: Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptidesType: ApplicationFiled: June 11, 2010Publication date: July 12, 2012Inventors: Billy G. Hudson, Roberto Vanacore, Gautam Bhave, Vadim Pedchenko
-
Patent number: 8216580Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: GrantFiled: June 27, 2008Date of Patent: July 10, 2012Assignee: The Regents of the University of CaliforniaInventors: Roman Nawroth, Steven D. Rosen
-
Patent number: 8211434Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: November 23, 2009Date of Patent: July 3, 2012Assignee: Allergan, Inc.Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Publication number: 20120141480Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: January 17, 2012Publication date: June 7, 2012Applicant: Genentech Inc.Inventors: Michael S.C. Fung, William N.C. Sun, Cecily R.Y. Sun
-
Publication number: 20120114660Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: ApplicationFiled: July 15, 2009Publication date: May 10, 2012Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
-
Publication number: 20120093829Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: ApplicationFiled: April 6, 2010Publication date: April 19, 2012Inventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
-
Publication number: 20120093828Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.Type: ApplicationFiled: March 19, 2010Publication date: April 19, 2012Inventors: Ashraf S. Ibrahim, Brad J. Spellberg, Yue Fu, John E. Edwards
-
Patent number: 8153132Abstract: Antibodies immunoreactive to mutant Pseudomonas HPPD are provided, and in an embodiment the mutant HPPD is one in which the wild-type HPPD is substituted at residue 336 with tryptophan for glycine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: October 30, 2009Date of Patent: April 10, 2012Assignee: MS Technologies, Inc.Inventors: Vaithilingam Sekar, Bruce Held, Kyu Chung, Paul F. Russell, Jr.
-
Publication number: 20120082676Abstract: One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.Type: ApplicationFiled: March 29, 2010Publication date: April 5, 2012Applicant: The Research Foundation of State University of New YorkInventor: Berhane Ghebrehiwet
-
Patent number: 8147836Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.Type: GrantFiled: December 17, 2008Date of Patent: April 3, 2012Assignee: Dyax Corp.Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
-
Patent number: 8142791Abstract: The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.Type: GrantFiled: November 23, 2007Date of Patent: March 27, 2012Assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen RechtsInventors: Volker Schirrmacher, Philipp Beckhove, Philippe Fournier, Maximilian Aigner
-
Patent number: 8119137Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.Type: GrantFiled: December 20, 2005Date of Patent: February 21, 2012Assignee: CSL Behring GmbHInventors: Bernhard Nieswandt, Thomas Renné
-
Patent number: 8114968Abstract: Proteins that bind to matrix metalloproteinase 12 and methods of using such proteins are described.Type: GrantFiled: March 3, 2009Date of Patent: February 14, 2012Assignee: Dyax Corp.Inventors: Laetitia Devy, Sonia Schoonbroodt, Rene Hoet, Nicholas Frans
-
Patent number: 8106168Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.Type: GrantFiled: May 7, 2010Date of Patent: January 31, 2012Assignee: Dyax Corp.Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
-
Patent number: 8105789Abstract: A compound capable of specifically binding to pathogen EF-1? but not host EF-1?, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22.Type: GrantFiled: June 30, 2009Date of Patent: January 31, 2012Assignee: The University of British ColumbiaInventors: Neil E. Reiner, Artem Tcherkassov, Devki Nandan
-
Publication number: 20110318359Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.Type: ApplicationFiled: December 2, 2009Publication date: December 29, 2011Inventors: Edward P. Feener, Allen Clermont
-
Publication number: 20110311549Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 8, 2011Publication date: December 22, 2011Applicants: LEICESTER, UNIVERSITY OF, OMEROS CORPORATIONInventors: Hans-Wilhelm Schwaeble, Clark E. Tedford, James B. Parent, Thomas Dudler, Gregory A. Demopulos
-
Publication number: 20110305701Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: ApplicationFiled: June 8, 2011Publication date: December 15, 2011Inventors: Neil R. Cashman, Joachim Bernhard Ostermann, Avijit Chakrabartty, Rishi Rakhit
-
Publication number: 20110305706Abstract: The present invention relates to methods for restoring fast axonal transport in a cell affected by oligomeric amyloid beta and for treating an oligomeric amyloid beta-mediated disease such as Alzheimer's disease using a Casein Kinase 2 inhibitor and, in some embodiments, a Glycogen Synthase Kinase 3 inhibitor.Type: ApplicationFiled: February 22, 2010Publication date: December 15, 2011Inventors: Scott Thomas Brady, Gerardo Andres Morfini, Gustavo Pigino
-
Patent number: 8062635Abstract: The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.Type: GrantFiled: October 8, 2004Date of Patent: November 22, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Taro Miyazaki, Tetsuhiro Soeda
-
Publication number: 20110274699Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.Type: ApplicationFiled: May 25, 2011Publication date: November 10, 2011Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis